Browse the latest research summaries in the field of immunology for spinal cord injury patients and caregivers.
Showing 181-190 of 730 results
Int. J. Mol. Sci., 2024 • December 26, 2023
This study investigates the potential of AKBA to ameliorate neuronal damage induced by acute spinal cord injury and elucidates the underlying mechanisms. The study found that AKBA, by engaging the Nrf...
KEY FINDING: AKBA reduces the expression of the pyroptotic initiator protein Caspase-1 by engaging the Nrf2-ROS-NLRP3 pathway, thus mitigating pyroptosis.
Scientific Reports, 2024 • January 23, 2024
This study elucidates the role of blood-derived monocytes in the pathogenesis of NMO using an NMO-like mouse model. It observes marker changes in monocytes/macrophages and microglia at different time ...
KEY FINDING: Monocytes infiltrate the brain during the early stages of NMO-like pathology and are associated with the inflammatory response.
Mediators of Inflammation, 2024 • January 5, 2024
The study aimed to identify key biomarkers related to immune infiltration and osteoclast differentiation in ankylosing spondylitis (AS) using bioinformatic methods on publicly available microarray dat...
KEY FINDING: 125 DEGs were identified, consisting of 36 upregulated and 89 downregulated genes that are involved in the cell cycle and replication processes.
Cell Reports, 2024 • February 27, 2024
Microglia are implicated as primarily detrimental in pain models; however, they exist across a continuum of states that contribute to homeostasis or pathology depending on timing and context. Unexpect...
KEY FINDING: Microglia depletion and repopulation at the acute-to-chronic transition completely resolved pain and improved peripheral inflammation.
Molecular Pain, 2024 • January 23, 2024
This study aimed to investigate the anti-nociceptive effect of PD1 and investigate its molecular mechanism involving neuro-inflammatory processes. Our findings strongly suggest that PD1 exerts its analg...
KEY FINDING: PD1 significantly reversed the NCLDH-induced imbalance in neuro-inflammatory response and alleviated the symptoms of mechanical and thermal hyperalgesia.
Tissue Eng Regen Med, 2024 • February 3, 2024
This study investigates the effects of a-gal nanoparticles on spinal cord injury (SCI) in a-gal knock-out mice. The nanoparticles are injected directly into the injured spinal cord to modulate the imm...
KEY FINDING: A-gal nanoparticles increased the recruitment of anti-inflammatory macrophages to the injury site and promoted the production of anti-inflammatory markers.
Heliyon, 2024 • January 26, 2024
This study investigates the therapeutic effects and mechanisms of Sarsasapogenin (SA) against spinal cord injury (SCI) by integrating network pharmacology analysis and experimental verification. Netwo...
KEY FINDING: SA targets key proteins like TNF, RELA, JUN, MAPK14, and MAPK8, suggesting its potential to treat SCI by modulating inflammation-related signaling pathways.
The Journal of Neuroscience, 2024 • February 7, 2024
This study investigates the role of TLR4 signaling in chronic SCI using TLR4 null and wild-type mice, focusing on molecular, cellular, and ECM changes at 1 day, 7 days, and 8 weeks post-injury. The re...
KEY FINDING: TLR4 deletion reduces neuronal and myelin loss, decreasing secondary damage at 8 weeks post-SCI.
CNS Neurosci Ther, 2024 • January 1, 2024
Interleukin (IL)-38 is a newly discovered cytokine of the IL-1 family, which binds various receptors (i.e., IL-36R, IL-1 receptor accessory protein-like 1, and IL-1R1) in the central nervous system (C...
KEY FINDING: IL-38 alleviates neuromyelitis optica disorder (NMOD) by inhibiting Th17 expression.
Int. J. Mol. Sci., 2024 • January 26, 2024
The treatment of spinal cord injury (SCI) with uncultivated human bone marrow-derived stromal cells (bmSCs) prepared by negative selection has been proposed to be therapeutically superior to treatment...
KEY FINDING: Treatment resulted in a significant, dose-dependent therapeutic effect on the recovery of motor performance.